Efficacy and safety of recombinant human activated protein C for severe sepsis - Wikidata - wikimedia - TriplyDB

Efficacy and safety of recombinant human activated protein C for severe sepsis

Efficacy and safety of recombinant human activated protein C for severe sepsis

http://www.wikidata.org/entity/Q29547839

about

Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels.Clinical trials in severe sepsis with drotrecogin alfa (activated)Physiological-dose steroid therapy in sepsis [ISRCTN36253388]ProCMD: a database and 3D web resource for protein C mutants Prospective evaluation of an internet-linked handheld computer critical care knowledge access system Anti-endotoxin vaccines: back to the future Immunomodulation in sepsis: state of the art and future perspective Hydroxymethylglutaryl-CoA reductase inhibitors (statins) for the treatment of sepsis Ulinastatin and thymosin as immune modulators for the treatment of sepsis Recombinant human activated protein C for severe sepsis in neonates Human recombinant activated protein C for severe sepsis Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients Ulinastatin and thymosin as immune modulators for the treatment of sepsis Human recombinant activated protein C for severe sepsis Antithrombin III for critically ill patients Human recombinant activated protein C for severe sepsis Granulocyte-Colony Stimulating Factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults Recombinant human activated protein C for severe sepsis in neonates Granulocyte-Colony Stimulating Factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults Antithrombin III for critically ill patients Challenging orthodoxy in critical care trial design: physiological responsiveness Learning from mistakes in clinical practice guidelines: the case of perioperative β-blockade Melioidosis: epidemiology, pathophysiology, and management.Drotrecogin alfa (activated): the first FDA-approved treatment for severe sepsis Prospects for vaccine prevention of meningococcal infection Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis Plasmodium falciparum histones induce endothelial proinflammatory response and barrier dysfunction Use of human protein C concentrates in the treatment of patients with severe congenital protein C deficiency Polyphosphate and omptins: novel bacterial procoagulant agents The microcirculation is the motor of sepsis The effect of a quantitative resuscitation strategy on mortality in patients with sepsis: a meta-analysis Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008 Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells Lipopolysaccharide endotoxins Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality Bench-to-bedside review: understanding genetic predisposition to sepsis Effect of hemofiltration filter adsorption on circulating IL-6 levels in septic rats Science review: role of coagulation protease cascades in sepsis Coagulation cascade in sepsis: getting from bench to bedside?Bench-to-bedside review: endothelial cell dysfunction in severe sepsis: a role in organ dysfunction?

P2860

Q21092899-FB4FE92B-A23C-4421-B6A5-5DE2D597308E Q21195024-BCD559D3-7451-489C-B6AC-73E669DE269F Q21195121-F51D43C9-16F7-4CB1-9E58-4B71252249DC Q21284212-CE8AF183-3F06-4C4F-AD5C-3134287F032A Q22000241-E69D9C0E-6F3C-4EA3-8148-5A52574D258F Q22305428-7D61BC3D-4F5C-4CE6-8CD7-553D04347DA9 Q22305766-6D8C219B-D2CC-4D7A-A85A-48168309D94F Q24193361-04E0B810-8D53-4C28-956C-AAEF489193CC Q24193380-EBCB8E83-D466-4AD8-BB30-8325D428B3A0 Q24200439-462F4DAC-34AE-4BD5-9432-48598541E1B4 Q24201123-8CF6F068-3B5D-43B0-9E8F-761B5F81BE6E Q24202128-F2814B56-8AD4-4504-8B86-2561F4C50509 Q24202365-459F4F2E-47E0-48A5-B6A4-A9E2D089611A Q24235181-26B260D5-1F65-413A-9C14-8F847AC08CD4 Q24242053-495E588A-1245-4FD9-810C-C85B3A0DEC79 Q24242859-37B70653-FC20-4583-8B29-1F2DAA65CC90 Q24245539-A91AE8BA-087D-44CB-AD84-942E30B1314A Q24246064-D62B19C6-7EB7-497A-B4A0-3DAEFD81671F Q24246628-8F425D09-93AC-426D-A006-A9F441128F93 Q24246826-D77DD34B-790F-4580-BCE8-FB406C97BF8C Q24282584-F3C18C1E-1DF3-44C0-97CA-C309B2F1683D Q24289034-06856167-0BBE-4506-919C-D9486C3A0A2F Q24522461-64C819EA-EE1C-40B2-AC7A-BF261FCE331C Q24536981-B36B0CB7-D191-4AA1-AFEF-BF40542D78B7 Q24537338-9A35DD84-997E-4672-952B-583FE3406BC5 Q24568212-06EE3A4E-B762-4303-BD8E-4BC27C0553FE Q24597556-8B514B32-32FC-427D-B2C9-59E8F200B20B Q24612253-C11BAE0F-D339-4024-BD75-D4AAA864212B Q24629548-BAA69547-19EF-4BE4-A12E-89B223E16F97 Q24633735-3E6E3D79-D91D-46F9-AB9F-827C1F93F965 Q24642798-397E9284-5B45-4280-A13E-3194DB4092B5 Q24644984-BAB60D6B-1364-4FBA-B023-8737C231607C Q24646845-B95453FD-F2A5-4407-84C8-CB2799E29655 Q24650970-A4537A8B-40F6-4198-BD7E-D9926EB8A7E8 Q24676668-3DE78032-D7B9-4B9C-AEFA-A17F76BBF48F Q24791408-89A5FA86-EED2-4696-B640-66C191887674 Q24792635-66E898B3-A596-4F81-8EAA-8BB71AD7F266 Q24794146-B6D31F52-1877-4BB8-A0CD-225A2AF9A5DA Q24794170-010E0E12-EC10-4C44-9422-A76CDE906061 Q24794238-9CDD5B19-48A6-443A-9524-BA53F702A27D

P2860

Efficacy and safety of recombinant human activated protein C for severe sepsis

http://www.wikidata.org/entity/Q29547839

description

2001 nî lūn-bûn

@nan

2001 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի մարտին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Efficacy and safety of recombinant human activated protein C for severe sepsis

@ast

Efficacy and safety of recombinant human activated protein C for severe sepsis

@en

type

label

Efficacy and safety of recombinant human activated protein C for severe sepsis

@ast

Efficacy and safety of recombinant human activated protein C for severe sepsis

@en

prefLabel

Efficacy and safety of recombinant human activated protein C for severe sepsis

@ast

Efficacy and safety of recombinant human activated protein C for severe sepsis

@en

P1433

Q29547839-568A7C9E-7FED-4804-80A1-F2DA15346528

P1476

Q29547839-42B96A80-A7A6-4C94-901F-3C13D18A7F83

P2093

Q29547839-2515F15B-1C5A-4407-9D06-5D9E75CD5392

Q29547839-29419571-3AE3-4B1C-B7B2-CC5E1BEA773B

Q29547839-29D9C370-BEB4-48DF-A573-475E7BD23206

Q29547839-2B4FBBC9-AC17-43AC-9E4D-695C4865772F

Q29547839-370B53EF-67FC-4B06-A64A-1ED03C9E0039

Q29547839-4D8467A7-FB3D-4E2A-ABEA-76B0048F9FE1

Q29547839-5F3E52CB-2119-4706-95A3-8A569474AD84

Q29547839-65DDBFBA-213A-4BAB-B27B-287A872274F2

Q29547839-7C55A2D9-31D6-42D3-B5D1-993707E501B2

Q29547839-C754420F-3189-4FC1-8320-F7366504F00F

P304

Q29547839-6AAA5AC0-27A5-4AF4-95DA-E90AEFF2CBED

P31

Q29547839-8A7688E8-BB95-4002-B7CB-B7E73AA912C5

P3181

Q29547839-CF4F5376-2B20-4E4A-9816-D71B3E9BD98C

P356

Q29547839-1ED8E03C-6A8C-43D6-A4E8-5EC3A5B1C63B

P407

Q29547839-6A460603-505B-4C06-944A-BE53425C607E

P433

Q29547839-995B458B-3C63-46BF-AC04-74898E784314

P478

Q29547839-5D62F787-9BE7-4504-A2FA-665B105332E5

P50

Q29547839-80666D15-990E-421F-BE97-32984B293761

Q29547839-A4DF60CF-3A0D-4151-AFAC-493FF9C7F069

P577

Q29547839-4733504F-6798-4379-98E9-0EE6192AF990

P698

Q29547839-DB8595BC-FF88-4E87-BF82-5C5F33AFB107

P921

Q29547839-A4E53317-51F8-407D-B219-8280F4EFB483

P3181

P356

NEJM200103083441001

P1433

The New England Journal of Medicine

P1476

Efficacy and safety of recombinant human activated protein C for severe sepsis

@en

P2093

A Lopez-Rodriguez

http://www.w3.org/2001/XMLSchema#string

C J Fisher

http://www.w3.org/2001/XMLSchema#string

G E Garber

http://www.w3.org/2001/XMLSchema#string

G R Bernard

http://www.w3.org/2001/XMLSchema#string

J D Helterbrand

http://www.w3.org/2001/XMLSchema#string

J F Dhainaut

http://www.w3.org/2001/XMLSchema#string

J S Steingrub

http://www.w3.org/2001/XMLSchema#string

P F Laterre

http://www.w3.org/2001/XMLSchema#string

Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group

http://www.w3.org/2001/XMLSchema#string

S P LaRosa

http://www.w3.org/2001/XMLSchema#string

P304

699-709

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

460879

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJM200103083441001

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

344

http://www.w3.org/2001/XMLSchema#string

P50

Eugene Wesley Ely

Jean-Louis Vincent

P577

2001-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11236773

http://www.w3.org/2001/XMLSchema#string

P921